Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade… Read more
Calidi Biotherapeutics Inc. (CLDI) - Total Assets
Latest total assets as of September 2025: $14.03 Million USD
Based on the latest financial reports, Calidi Biotherapeutics Inc. (CLDI) holds total assets worth $14.03 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Calidi Biotherapeutics Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Calidi Biotherapeutics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Calidi Biotherapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Calidi Biotherapeutics Inc.'s total assets of $14.03 Million consist of 72.1% current assets and 27.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 67.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Calidi Biotherapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Calidi Biotherapeutics Inc.'s current assets represent 72.1% of total assets in 2024, an increase from 27.7% in 2020.
- Cash Position: Cash and equivalents constituted 67.6% of total assets in 2024, up from 22.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Calidi Biotherapeutics Inc. Competitors by Total Assets
Key competitors of Calidi Biotherapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Calidi Biotherapeutics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Calidi Biotherapeutics Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Calidi Biotherapeutics Inc. is currently not profitable relative to its asset base.
Calidi Biotherapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.12 | 0.19 | 0.17 |
| Quick Ratio | 2.12 | 0.19 | 0.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.83 Million | $ -9.36 Million | $ -565.68K |
Calidi Biotherapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Calidi Biotherapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.37 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 41.6% |
| Total Assets | $14.18 Million |
| Market Capitalization | $1.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Calidi Biotherapeutics Inc.'s assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Calidi Biotherapeutics Inc.'s assets grew by 41.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Calidi Biotherapeutics Inc. (2020–2024)
The table below shows the annual total assets of Calidi Biotherapeutics Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.18 Million | +41.55% |
| 2023-12-31 | $10.02 Million | +285.79% |
| 2022-12-31 | $2.60 Million | -23.41% |
| 2021-12-31 | $3.39 Million | +83.10% |
| 2020-12-31 | $1.85 Million | -- |